Use of modified live feline panleukopenia virus vaccine to immunize dogs against canine parvovirus.
Modified live feline panleukopenia virus (FPLV) vaccine protected dogs against canine parvovirus (CPV) infection. However, unlike the long-lived (greater than or equal to 20-month) immunity engendered by CPV infection, the response of dogs to living FPLV was variable. Doses of FPLV (snow leopard strain) in excess of 10(5.7) TCID50 were necessary for uniform immunization; smaller inocula resulted in decreased success rates. The duration of immunity, as measured by the persistence of hemagglutination-inhibiting antibody, was related to the magnitude of the initial response to vaccination; dogs with vigorous initial responses resisted oronasal CPV challenge exposure 6 months after vaccination, and hemagglutination-inhibiting antibodies persisted in such dogs for greater than 1 year. Limited replication of FPLV in dogs was demonstrated, but unlike CPV, the feline virus did not spread to contact dogs or cats. Adverse reactions were not associated with living FPLV vaccination, and FPLV did not interfere with simultaneous response to attenuated canine distemper virus.
D000818:Animals; D000914:Antibodies, Viral / Q000096:biosynthesis; D004283:Dog Diseases / Q000382:microbiology / Q000517:prevention & control*; D004285:Dogs; D004306:Dose-Response Relationship, Immunologic; D028301:Feline Panleukopenia Virus / Q000254:growth & development / Q000276:immunology*; D010321:Parvoviridae / Q000276:immunology*; D014613:Vaccines, Attenuated / Q000276:immunology; D014765:Viral Vaccines / Q000276:immunology*; D014777:Virus Diseases / Q000382:microbiology / Q000517:prevention & control / Q000662:veterinary*; D014779:Virus Replication
D000914:Antibodies, Viral; D014613:Vaccines, Attenuated; D014765:Viral Vaccines